We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Prasad Adusumilli

Prasad S Adusumilli MD, FACS, FCCP

Associate Professor, Department of Cardiothoracic Surgery, Weill Cornell Medical Center; Associate Attending Surgeon, Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center (MSKCC); Member, Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, New York

Prasad Adusumilli is an Associate Attending Surgeon in the Thoracic Service in Department of Surgery (MSKCC), a Member in the Center for Cell Engineering (MSKCC), and an Associate Professor of Cardiothoracic Surgery at Weill Cornell Medical College.  He was specifically recruited to MSKCC to bolster the thoracic surgery translational research program within their Department of Surgery.

Over the past six years, his research has primarily focused on tumor immunology in thoracic malignancies and the development of T-cell-mediated immunotherapy for thoracic malignancies and pleural-based diseases. In recent years, Dr. Adusumilli has devoted his efforts to develop mesothelin-targeted immunotherapy for lung cancer and malignant pleural mesothelioma. This work has led to convincing data showing that T-cells work efficiently when targeted to the tumor microenvironment. The strength of his research is the ability to noninvasively track, monitor, and measure lung cancer tumor burden and T-cell trafficking in an effort to better understand the biology of lung cancers and the efficacy of novel treatments. Dr. Adusumilli’s goal is to transition his work toward adoptive T-cell therapy clinical trial to lung cancer patients within this year.